Back to Search
Start Over
Developments and opportunities in continuous biopharmaceutical manufacturing
- Source :
- mAbs, article-version (VoR) Version of Record
- Publication Year :
- 2021
- Publisher :
- Taylor & Francis, 2021.
-
Abstract
- Today’s biologics manufacturing practices incur high costs to the drug makers, which can contribute to high prices for patients. Timely investment in the development and implementation of continuous biomanufacturing can increase the production of consistent-quality drugs at a lower cost and a faster pace, to meet growing demand. Efficient use of equipment, manufacturing footprint, and labor also offer the potential to improve drug accessibility. Although technological efforts enabling continuous biomanufacturing have commenced, challenges remain in the integration, monitoring, and control of traditionally segmented unit operations. Here, we discuss recent developments supporting the implementation of continuous biomanufacturing, along with their benefits.
- Subjects :
- Time Factors
Drug Industry
Cost-Benefit Analysis
Immunology
Review
Drug Costs
Unit (housing)
Biopharmaceuticals
Workflow
03 medical and health sciences
0302 clinical medicine
Immunology and Allergy
Production (economics)
Humans
Technology, Pharmaceutical
Biomanufacturing
biosimilars
continuous manufacturing
perfusion culture
Biosimilar Pharmaceuticals
030304 developmental biology
Pace
filtration
0303 health sciences
viral inactivation
Biological Products
bioprocessing
Biosimilar
Investment (macroeconomics)
process analytical technology
Biopharmaceutical manufacturing
Risk analysis (engineering)
030220 oncology & carcinogenesis
chromatography
Lower cost
Business
monoclonal antibodies
Biotechnology
Subjects
Details
- Language :
- English
- ISSN :
- 19420870 and 19420862
- Volume :
- 13
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- mAbs
- Accession number :
- edsair.doi.dedup.....e6d0f4fa3afa8b9d131bbd1aea89c196